Half-Year 2022 Financial and Clinical Trials Update
HY 2022: Diagnostics Division CER growth
By Region and Customer Area (vs. 2021)
Roche
Reported
Restatement³
Global
EMEA¹
NOA
CHFm %CER CHFm %CER CHFm %CER
APAC
CHFm %CER
LATAM
CHFm %CER
Global
NOA
CHFm %CER CHFm %CER CHFm %CER
EMEA¹
APAC
LATAM
CHFm %CER CHFm %CER
Core Lab 2,3
Point of Care³
Molecular Lab³
Diabetes Care
Pathology Lab
Diagnostics Div.
3,834 4
2,289
2,341
1,313 6
714
2
1,521 3
286 12
3,875 4
1,352 5
43
585
-53
802
600
830
714
72 -30
2,609 46
652 -50
716
974 333
1
1,521
908 713
3
286 12
75 -28
7
838 2
888
7
544
20
71
-19
1,980
1
732 2
714 -1
466 6
68
-21
832 -5
454 -3
116
-30
144
1
118
24
832
-5
652
10
160 11
348
8 132 13
12
30
652
10
160
454 -3 116 -30
11
144
1
118 24
348
8
132
13
12 30
50
9,948
11 3,350 -14 2,868
34
3,171 39
559
2
9,948
11 3,350-14 || 2,868
34 3,171
39
559
2
CER=Constant Exchange Rates; ' Europe, Middle East and Africa; 2 incl. Roche Information Solutions; 3 Sales in the Point of Care customer area include sales from the Liat business (POC molecular), and sales in the Core
Lab customer area include sales from the Life Science Alliances, both previously shown as part of Molecular Lab customer area. The comparative information for 2021 has been updated accordingly. In Q1 21 POC
molecular sales = 90mCHF, Q2 21=92mCHF, Q3 21=175mCHF, Q4 21=194mCHF. In Q1 21 LS Alliances = 21mCHF, Q2 21-23mCHF, Q3 21-23m CHF, Q4 21=20mCHF.
187View entire presentation